Effect of Gamma-Oryzanol as Therapeutic Agent to Prevent Cardiorenal Metabolic Syndrome in Animals Submitted to High Sugar-Fat Diet

Author(s):Show less -

Francisqueti, Fabiane Valentini ^[1] ; Minatel, Igor Otavio ^[2] ; Togneri Ferron, Artur Junio ^[1] ; Zanati Bazan, Silmeia Garcia ^[1] ; Silva, Vanessa dos Santos ^[1] ; Garcia, Jessica Leite ^[1] ; Salome de Campos, Dijon Henrique ^[1] ; Ferreira, Ana Lucia ^[1] ; Moreto, Fernando ^[1] ; Cicogna, Antonio Carlos ^[1] ; Correa, Camila Renata ^[1]

Affiliation

^[1] Sao Paulo State Univ Unesp, Sch Med, BR-18618687 Botucatu, SP - Brazil

^[2] Sao Paulo State Univ Unesp, Inst Biosci, BR-18618689 Botucatu, SP - Brazil

• Document type: Journal article
• Source: NUTRIENTS; v. 9, n. 12 DEC 2017.
• Web of Science Citations: 8

Abstract

Background: The high consumption of fat and sugar contributes to the development of obesity and co-morbidities, such as diabetes, and cardiovascular and kidney diseases. Different strategies have been used to prevent these diseases associated with obesity, such as changes in eating habits and/or the addition of dietary components with anti-inflammatory and anti-oxidant properties, such as gamma-oryzanol (Oz) present mainly in bran layers and rice germ. Methods: Animals were randomly divided into four experimental groups and fed ad libitum for 20 weeks with control diet (C, n = 8), control diet + Oz (C + Oz, n = 8), high-sugar and high-fat diet (HSF, n = 8), and high-sugar and high-fat diet + Oz (HSF + Oz, n = 8). HSF groups also received water + sucrose (25%). The dose of Oz was added to diets to reach 0.5% of final concentration (w/w). Evaluation in animals included food and caloric intake, body weight, plasma glucose, insulin, triglycerides, uric acid, HOMA-IR, glomerular filtration rate, protein/creatinine ratio, systolic blood pressure, and Doppler echocardiographic. Results: Animals that consumed the HSF diet had weight gain compared to group C, increased insulin, HOMA, glucose and triglycerides, there were also atrial and ventricular structural alterations, deterioration of systolic and diastolic function, decreased glomerular filtration rate, and proteinuria. Gamma-oryzanol is significantly protective against effects on body weight, hypertriglyceridemia, renal damage, and against structural and functional alteration of the heart. Conclusion: Gamma-oryzanol shows potential as a therapeutic to prevent Cardiorenal Metabolic Syndrome. (AU)

• FAPESP's process: 15/10626-0 - Interrelation of gamma-oryzanol and activation of adipose R1 and R2 adipose receptors: possible effect on improvement of obesity-associated renal function
• Grantee: Camila Renata Corrêa
• Support Opportunities: Regular Research Grants